JP2019017264A - Silkworm cocoon-derived component-containing health food - Google Patents
Silkworm cocoon-derived component-containing health food Download PDFInfo
- Publication number
- JP2019017264A JP2019017264A JP2017136148A JP2017136148A JP2019017264A JP 2019017264 A JP2019017264 A JP 2019017264A JP 2017136148 A JP2017136148 A JP 2017136148A JP 2017136148 A JP2017136148 A JP 2017136148A JP 2019017264 A JP2019017264 A JP 2019017264A
- Authority
- JP
- Japan
- Prior art keywords
- cocoon
- fibroin
- sericin
- health food
- derived component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 16
- 241000255789 Bombyx mori Species 0.000 title abstract description 7
- 240000000249 Morus alba Species 0.000 claims abstract description 45
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 45
- 108010022355 Fibroins Proteins 0.000 claims abstract description 37
- 108010013296 Sericins Proteins 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 13
- 238000009366 sericulture Methods 0.000 abstract description 11
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 10
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 10
- 239000000843 powder Substances 0.000 description 27
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 15
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 241000209094 Oryza Species 0.000 description 11
- 235000007164 Oryza sativa Nutrition 0.000 description 11
- 235000009566 rice Nutrition 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000195620 Euglena Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004071 soot Substances 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、蚕の繭から得られるフィブロインやセリシンと、桑の葉を含有する蚕繭由来成分含有健康食品に関するものである。 The present invention relates to a health food containing a cocoon-derived component containing fibroin or sericin obtained from cocoon cocoons and mulberry leaves.
日本における糖尿病人口は、予備軍を含めるとおよそ二千万人いるといわれており、そのうちの約９割は、遺伝的要因に過食（特に高脂肪食）、運動不足、肥満、メタボリック症候群、ストレス等の生活習慣や加齢といった要因が加わり発症する２型糖尿病である。 It is said that there are approximately 20 million people with diabetes in Japan, including the reserve army, and about 90% of them are overeating for genetic factors (especially high-fat diet), lack of exercise, obesity, metabolic syndrome, stress It is type 2 diabetes that develops due to factors such as lifestyle and aging.
この糖尿病の治療には、食事療法、運動療法といった生活習慣改善療法と、薬物療法の大きく分けて二つの治療方法があり、一般的には、初期の段階であれば、まず、前者の生活習慣の改善、具体的には、例えば、年齢、肥満度、血糖値等を考慮してエネルギー摂取量を決定し、過食、高脂肪食摂取を抑えると共に、少なくとも３〜５回／週、できれば毎日、１５０分以上の運動（そのうち、２０〜６０分はある程度負荷が高い有酸素運動）による治療が勧められ、この生活習慣の改善でも目標の血糖値に達しない場合は、薬物療法が行われる。 There are two main types of treatment for diabetes, lifestyle improvement therapy such as diet therapy and exercise therapy, and pharmacotherapy. Generally, at the initial stage, the former lifestyle Improvement, specifically, for example, determining the energy intake taking into account age, obesity, blood glucose level, etc., and suppressing overeating, high fat diet intake, at least 3-5 times per week, preferably daily, Treatment with an exercise of 150 minutes or longer (of which 20 to 60 minutes is aerobic exercise with a high load to some extent) is recommended, and drug therapy is performed when the target blood glucose level is not reached even with this lifestyle improvement.
この薬物療法では、一般的にはインスリン注射ではなく、飲み薬だけで対応する場合が多く、例えば、インスリンの分泌を促すインクレチン関連薬、スルフォルニ尿素薬、グリニド薬、インスリンの効きを良くするピグマナイド薬、チアゾリジン薬、そして、食後の血糖の上昇を抑えるα−グルコシダーゼ阻害薬などが一般的に用いられる。また、α−グルコシダーゼ阻害薬に関しては、糖尿病患者だけでなく、糖尿病予備軍である境界型の人にも予防的に使用されることもある。 In this drug therapy, in general, it is often handled only by taking medicine instead of insulin injection, for example, incretin-related drugs that promote insulin secretion, sulforniurea drugs, glinide drugs, pigmanide that improves insulin efficacy Drugs, thiazolidine drugs, and α-glucosidase inhibitors that suppress an increase in blood glucose after meals are generally used. In addition, the α-glucosidase inhibitor may be used prophylactically not only for diabetic patients but also for borderline persons who are diabetic reserves.
このような血糖値上昇抑制剤に関しては、近年、桑の葉に含まれる１−デオキシノジリマイシン（ＤＮＪ）に血糖値の上昇を抑制する効果があることが確認され、この桑の葉を有効成分とした血糖値上昇抑制剤や健康補助食品に関する研究が進み、例えば特許文献１〜４のような様々な血糖値上昇抑制剤や健康補助食品に関する特許出願がなされている。 With regard to such a blood sugar level increase inhibitor, it has recently been confirmed that 1-deoxynojirimycin (DNJ) contained in mulberry leaves has an effect of suppressing an increase in blood sugar level. Research on blood glucose level elevation inhibitors and health supplements has progressed, and patent applications relating to various blood glucose level elevation inhibitors and health supplements, such as Patent Documents 1 to 4, have been made.
また、この桑の葉を餌とする蚕が産生する絹糸（シルク）は、フィブロインとセリシンとの二種類のタンパク質で構成されるものであり、主成分であるフィブロインは、従来、セリシンを除去した後、繊維用途（絹糸）に利用されるのが一般的であったが、近年、このフィブロインのタンパク質としての研究が進み、医薬品、食品分野に応用されるようになり、食べるシルクとして注目を集めている。 In addition, the silk thread (silk) produced by cocoons that feed on mulberry leaves is composed of two types of proteins, fibroin and sericin, and fibroin, the main ingredient, has conventionally removed sericin. Later, it was generally used for textiles (silk), but in recent years, research on fibroin as a protein has progressed, and it has been applied to the fields of pharmaceuticals and foods. ing.
この蚕の絹糸（繭）から得られるフィブロイン（シルクフィブロイン）は、高吸脂性であるとともに難消化性であるため、摂取すると体内で脂肪（コレステロール）を吸着し、腸管で吸収されずに脂肪を吸着した状態のまま体外へ排出され、これにより、中性脂肪値の低下作用、血糖値の低下作用、ヘモグロビンＡ１ｃ値の低下作用、コレステロールの低下作用・正常化作用をもたらすことから、ダイエット食品やメタボリック症候群の改善剤、予防剤として用いられている。 Fibroin (silk fibroin) obtained from silkworm silk thread (silk) is highly absorbent and indigestible, so when ingested it absorbs fat (cholesterol) in the body and is not absorbed by the intestinal tract. Dietary food because it is discharged to the outside of the body in an adsorbed state, thereby bringing about a neutral fat level lowering action, a blood sugar level lowering action, a hemoglobin A1c value lowering action, a cholesterol lowering action / normalizing action. It is used as a remedy or preventive for metabolic syndrome.
また、フィブロインから分離されたセリシンは、従来、保湿効果、抗酸化活性、チロシナーゼ阻害活性、紫外線カット機能を有することが知られており、主に化粧品関連に用いられていたが、近年、このセリシンに関しても様々な研究が進み、このセリシンには、上記の効果以外に、便秘改善効果、大腸がん発現抑制効果、ミネラル吸収促進作用があることが確認され、前述したフィブロイン同様、医薬品、食品分野にも応用されるようになっている。 In addition, sericin isolated from fibroin has been conventionally known to have a moisturizing effect, antioxidant activity, tyrosinase inhibitory activity, and UV-blocking function, and has been used mainly in cosmetics. In addition to the above effects, this sericin has been confirmed to have a constipation improving effect, a colon cancer expression suppressing effect, and a mineral absorption promoting effect, as well as the aforementioned fibroin. It has come to be applied to.
このように、蚕に関連した素材（成分）には糖尿病患者やその予備軍、更にはメタボリック症候群対象者に対して有効な改善・予防効果を発揮する有用成分が含まれている。 Thus, the material (component) related to hemorrhoids includes useful components that exhibit an effective improvement / prevention effect for diabetic patients, their reserves, and further subjects with metabolic syndrome.
ところで、前述したように、繭は蚕が産生するものであるから、養蚕を営むもの（例えば養蚕農家や養蚕事業者）であれば、これら蚕由来成分（蚕の繭や桑の葉）は極めて容易に入手することが可能である。 By the way, as described above, cocoons are produced by cocoons, so if they are cultivated (for example, sericulture farmers or sericulture operators), these cocoon-derived components (such as cocoon cocoons and mulberry leaves) are extremely It can be easily obtained.
本発明者は、養蚕事業の一環として、容易に入手することが可能な蚕の繭や桑の葉を用い、容易に且つ安価に新たな健康食品を製造することができると考え、本発明を見出した。 The present inventor believes that as a part of the sericulture business, it is possible to easily and inexpensively produce new health foods using easily available cocoon cocoons and mulberry leaves. I found it.
即ち、本発明は、養蚕農家や養蚕事業者などの養蚕を営むものが容易に入手可能な蚕由来成分（蚕の繭や桑の葉）を用い、糖尿病患者やその予備軍並びにメタボリック症候群対象者に対して有用な蚕繭由来成分含有健康食品を提供することを目的とする。 In other words, the present invention uses a cocoon-derived component (a cocoon cocoon or mulberry leaf) that can be readily obtained by sericulture farmers, sericulture operators, etc. An object of the present invention is to provide a health food containing a koji-derived component that is useful for the above.
本発明の要旨を説明する。 The gist of the present invention will be described.
蚕の繭から得られるフィブロイン、又は蚕の繭から得られるセリシンの少なくともいずれか一方と、桑の葉とを有効成分として含有することを特徴とする蚕繭由来成分含有健康食品に係るものである。 The present invention relates to a cocoon-derived component-containing health food comprising, as active ingredients, at least one of fibroin obtained from cocoon cocoons or sericin obtained from cocoon cocoons and mulberry leaves .
また、蚕の繭から得られるフィブロインと、蚕の繭から得られるセリシンと、桑の葉とを有効成分として含有することを特徴とする蚕繭由来成分含有健康食品に係るものである。 In addition, the present invention relates to a health food containing a koji-derived component, comprising fibroin obtained from koji koji, sericin obtained from koji koji, and mulberry leaves as active ingredients.
また、前記フィブロイン、前記セリシン、及び前記桑の葉は、粉末化されているものであることを特徴とする請求項２記載の蚕繭由来成分含有健康食品に係るものである。 Moreover, the said fibroin, the said sericin, and the said mulberry leaf are powdered, It concerns on the health food containing a cocoon origin component of Claim 2 characterized by the above-mentioned.
本発明は上述のように構成したから、蚕の繭に含まれるフィブロインやセリシンといった糖尿病患者やその予備軍並びにメタボリック症候群対象者に対して有用な成分と、桑の葉に含まれる豊富な１−デオキシノジリマイシンを、容易に且つ同時に摂取することができる。 Since the present invention is configured as described above, it is useful for diabetic patients such as fibroin and sericin contained in cocoon moths, reserves thereof, and subjects with metabolic syndrome, and abundant 1- Deoxynojirimycin can be taken easily and simultaneously.
また、本発明は、例えば養蚕事業者が実施すれば、蚕の繭は自身が生産しているものであるから容易に入手可能であるし、また、桑の葉も蚕の餌としてその入手手段が確立されているので容易に入手することが可能であり、よって、原材料費、流通費などの製造コストを抑えることができるので、製品を安価に提供することが可能となる。 In addition, the present invention can be easily obtained because, for example, a sericulture operator implements cocoon cocoons because they are produced by themselves, and mulberry leaves can also be used as a means of obtaining cocoons. Therefore, it is possible to obtain the product at low cost because manufacturing costs such as raw material costs and distribution costs can be suppressed.
好適と考える本発明の実施形態を、本発明の作用を示して簡単に説明する。 The preferred embodiment of the present invention will be briefly described by showing the operation of the present invention.
本発明を摂取することで、蚕の繭由来のフィブロインやセリシンと、桑の葉由来の１−デオキシノジリマイシンとを同時に摂取することができ、各成分が夫々有効に作用する。 By ingesting the present invention, it is possible to simultaneously ingest fibroin and sericin derived from persimmon mushrooms and 1-deoxynojirimycin derived from mulberry leaves, and each component acts effectively.
即ち、例えば、フィブロインとセリシンの両方を含有する構成とすれば、本発明の摂取により、フィブロインにより脂肪の蓄積が抑制され、更に、セリシンにより便秘が改善され、ミネラルの吸収も促進されるので、肥満体質の改善が図られ、メタボリック症候群の予防又は改善が図られる。 That is, for example, if it is configured to contain both fibroin and sericin, the intake of the present invention suppresses fat accumulation by fibroin, and further improves constipation and promotes mineral absorption by sericin. The obesity constitution is improved, and metabolic syndrome is prevented or ameliorated.
また、桑の葉由来の１−デオキシノジリマイシンにより糖の腸からの吸収が抑制されて食後の血糖値の急激な上昇が抑制されるので、糖尿病の症状が緩和される。 Moreover, 1-deoxynojirimycin derived from mulberry leaves suppresses absorption of sugar from the intestine and suppresses a rapid increase in blood glucose level after meals, thereby alleviating the symptoms of diabetes.
また、本発明は、養蚕事業者であれば、その原材料となる蚕の繭は自給することができ、また、桑の葉も蚕の飼料として容易に入手可能なので、原材料費、流通費などの製造コストを抑えることができ、製品を安価に提供することが可能となる。 In addition, since the present invention is a sericulture company, the straw of the straw that is the raw material can be self-sufficient, and the mulberry leaf can be easily obtained as the feed of the straw, so the raw material cost, the distribution cost, etc. Manufacturing costs can be reduced, and products can be provided at low cost.
本発明の具体的な実施例について説明する。 Specific examples of the present invention will be described.
本実施例は、蚕の繭から得られるフィブロインと、蚕の繭から得られるセリシンと、桑の葉とを有効成分として含有する蚕繭由来成分含有健康食品である。 The present example is a cocoon-derived component-containing health food containing, as active ingredients, fibroin obtained from cocoon cocoons, sericin obtained from cocoon cocoons, and mulberry leaves.
具体的には、本実施例の蚕繭由来成分含有健康食品は、みどり繭から得られるフィブロインを粉末化したフィブロイン粉末と、同様にみどり繭から得られるセリシンを粉末化したセリシン粉末と、桑の葉を粉末化した桑の葉粉末とが混合されてなり、その最終形態は、粉末のまま、若しくは、錠剤又はカプセル剤など固形状に形成されてなるものである。 Specifically, the cocoon-derived component-containing health food of this example includes fibroin powder obtained by pulverizing fibroin obtained from green potato, sericin powder obtained by pulverizing sericin obtained from green potato, and mulberry The mulberry leaf powder obtained by pulverizing the leaves is mixed, and the final form is a powder or is formed into a solid form such as a tablet or a capsule.
より具体的には、本実施例のフィブロイン粉末とセリシン粉末は、みどり繭をそのまま凍結乾燥機にて予備凍結（−４５℃、３時間）し、この予備凍結したみどり繭を乾燥（４０℃、０．１Ｔｏｒｒ、２６時間）して凍結乾燥状態にし、この凍結乾燥状態となったみどり繭を粉砕機で粉砕して粉末化して得られるみどり繭粉末である。 More specifically, the fibroin powder and sericin powder of this Example were prepared by pre-freezing the green rice cake with a freeze dryer (−45 ° C., 3 hours), and drying the pre-frozen green rice cake (40 ° C., This powder is obtained by pulverizing the freeze-dried green rice cake with a pulverizer in a freeze-dried state (0.1 Torr, 26 hours).
即ち、本実施例のフィブロイン粉末及びセリシン粉末は、みどり繭そのものを粉末化したみどり繭粉末であり、みどり繭が本来含んでいるフィブロイン、セリシンの双方の成分をそのまま含有するものである。 That is, the fibroin powder and sericin powder of the present example are green rice cake powder obtained by pulverizing the green rice cake itself, and contain both the components of fibroin and sericin originally contained in the green rice cake.
また、上記方法では原材料となるみどり繭の総重量に対して得られるみどり繭粉末の割合（繭重量回収率）は約８０％である。また、みどり繭の平均重量は約４００ｇであるから、本実施例のみどり繭粉末、すなわち、フィブロイン粉末及びセリシン粉末を１ｇ得るには、およそ３個のみどり繭が必要となる。即ち、言い換えると、本実施例のみどり繭粉末１ｇあたり、およそ３個分のみどり繭の有用成分が含まれることとなる。 Further, in the above method, the ratio of green soot powder obtained (the soot weight recovery rate) to the total weight of green soy as a raw material is about 80%. Further, since the average weight of the green rice cake is about 400 g, about 3 green rice cakes are required to obtain 1 g of the green rice powder of this example, that is, fibroin powder and sericin powder. That is, in other words, about 3 pieces of useful components of green rice cake are contained per 1 g of green rice cake powder of this example.
なお、本実施例では、上述のようにみどり繭を採用する構成とされているが、繭は、これに限定されるものではなく、白繭でも良い。 In this embodiment, as described above, the green cocoon is adopted. However, the cocoon is not limited to this, and white cocoon may be used.
また、この繭を産生する蚕についても、無菌養蚕、家蚕のいずれのものを採用する構成としても良い（本実施例では、無菌養蚕を採用した構成とされている。）。 Also, the cocoon that produces this cocoon may employ either a sterile sericulture or a rabbit (in this embodiment, a sterilized sericulture is adopted).
また、本実施例では、フィブロイン粉末とセリシン粉末をみどり繭粉末として予め混合されている状態のものが採用されているが、公知の方法により、繭からフィブロインを抽出し、更にこのフィブロインからセリシンを分離抽出し、夫々を別々に粉末化しても良い。 Further, in this example, a fibroin powder and a sericin powder are mixed in advance as a green soot powder, but fibroin is extracted from the koji by a known method, and sericin is further extracted from this fibroin. They may be separated and extracted and each powdered separately.
また更に、粉末化する前にペプチド化し、このペプチド化したものを粉末化しても良い。 Furthermore, it may be converted into a peptide before pulverization, and this peptide may be pulverized.
また、本実施例の桑の葉粉末は、一般的な茶葉を製造する方法と同法（本実施例では、裁断した生の桑の葉を蒸して殺菌した後、乾燥機にて乾燥（約１００℃））で乾燥状態にし、この乾燥状態となった桑の葉を粉砕機で粉砕して粉末化したものである。 Further, the mulberry leaf powder of this example is the same as the method for producing general tea leaves (in this example, steamed sterilized raw mulberry leaves are sterilized and then dried (about The dried mulberry leaves are pulverized by a pulverizer and powdered.
また、上記方法では原材料となる桑の葉（乾燥桑の葉）の総重量に対して得られる桑の葉粉末の割合（桑の葉重量回収率）はほぼ１００％である。よって、桑の葉１ｇ（小さい桑の葉１枚分程度）から１ｇの桑の葉粉末が得られる。 In the above method, the ratio of the mulberry leaf powder obtained (the mulberry leaf weight recovery rate) to the total weight of the mulberry leaves (dried mulberry leaves) as the raw material is almost 100%. Therefore, 1 g of mulberry leaf powder can be obtained from 1 g of mulberry leaves (about one small mulberry leaf).
本実施例の蚕繭由来成分含有健康食品は、上述のみどり繭粉末（フィブロイン粉末及びセリシン粉末）と桑の葉粉末が１：１の混合比で混合されてなる混合粉末が経口用カプセルに充填されてなるカプセル剤として形成されたものである。 The cocoon-derived component-containing health food of this example is filled with a mixed powder obtained by mixing the above green powder (fibroin powder and sericin powder) and mulberry leaf powder in a mixing ratio of 1: 1. It is formed as a capsule.
このように、本実施例は、蚕の繭に含まれるフィブロインとセリシン、そして、蚕が餌として摂取する桑の葉を主成分とする蚕繭由来成分含有健康食品であるから、本実施例を摂取することで、フィブロイン、セリシン、桑の葉成分を同時に摂取することができる。そして、例えば、糖尿病患者やその予備軍が本実施例を摂取することで、みどり繭粉末に含まれるフィブロイン（シルクフィブロイン）の効果による中性脂肪値の低下、ヘモグロビンＡ１ｃ値の低下、コレステロールの低下・正常化と、セリシンの効果による便秘改善、ミネラル吸収促進などがもたらされ、更に、桑の葉に含まれる１−デオキシノジリマイシンの効果により、食後の血糖値の上昇が抑制され、糖尿病の症状が緩和されるだけでなく、メタボリック症候群の改善も図れる。 In this way, this example is a health food containing a cocoon-derived component mainly composed of fibroin and sericin contained in the cocoon cocoon and mulberry leaves taken by the cocoon as food. By ingesting, fibroin, sericin, and mulberry leaf components can be ingested simultaneously. And, for example, when a diabetic patient or a reserve arm ingests the present embodiment, a decrease in neutral fat value, a decrease in hemoglobin A1c value, a decrease in cholesterol due to the effect of fibroin (silk fibroin) contained in green powder・ Normalization, improvement of constipation due to the effect of sericin, promotion of mineral absorption, etc., and further, the effect of 1-deoxynojirimycin contained in mulberry leaves suppresses the increase in blood glucose level after meals. Not only the symptoms are alleviated, but also metabolic syndrome can be improved.
また、桑の葉には１−デオキシノジリマイシンだけでなく、カルシウムも豊富（牛乳の２０倍以上）に含まれているので、本実施例を摂取することにより、摂取量が不足気味であるカルシウム成分を極めて容易に摂取することができる。 In addition, mulberry leaves contain not only 1-deoxynojirimycin but also calcium (20 times more than milk), so by taking this example, the amount of intake of calcium is insufficient. Ingredients can be taken very easily.
また、この桑の葉の繊維質はセリシンと同様に便秘改善効果を発揮するので、セリシンによる便秘改善効果をより一層効果的なものとする。 Moreover, since the fiber of this mulberry leaf exhibits the constipation improving effect similarly to sericin, the constipation improving effect by sericin is made more effective.
また更に、桑の葉にはケルセチン−３−マロニルグルコシド（Ｑ３ＭＧ）が含まれており、このＱ３ＭＧはＬＤＬ（Low-density lipoprotein）の酸化を抑え、悪玉コレステロールの生成を抑制するので、動脈硬化を抑制する効果が得られる。 Furthermore, mulberry leaves contain quercetin-3-malonyl glucoside (Q3MG), which suppresses the oxidation of low-density lipoprotein (LDL) and suppresses the production of bad cholesterol, thus preventing arteriosclerosis. The effect of suppressing is acquired.
しかも、Ｑ３ＭＧは、肝臓のストレスを改善し、吸収された糖分を筋肉のエネルギー消費に利用して血糖値を低下させるので、この桑の葉に含まれる１−デオキシノジリマイシンとの相乗効果で、糖尿病患者やその予備軍が摂取することで、より一層、食後の血糖値の上昇の抑制効果が得られる。 In addition, Q3MG improves liver stress and reduces the blood sugar level by utilizing absorbed sugar for muscle energy consumption. Therefore, Q3MG has a synergistic effect with 1-deoxynojirimycin contained in this mulberry leaf, By taking it by diabetic patients and their reserves, it is possible to further suppress the increase in blood glucose level after meals.
また、本実施例の原材料である、みどり繭と桑の葉は、過剰摂取しても人体に有害な影響を及ぼさないことが確認されており、よって、糖尿病やその予備軍でない健康な人も安心して摂取することができ、これら健康な人が摂取することで、高血圧、メタボリック症候群、糖尿病の予防に効果が発揮され、健康維持が図られる。 In addition, it has been confirmed that the green mulberry and mulberry leaves, which are the raw materials of this example, do not have a harmful effect on the human body even if they are excessively consumed. It can be taken with peace of mind, and when taken by these healthy people, it is effective in preventing hypertension, metabolic syndrome, and diabetes, and maintaining health.
このように、本実施例は、みどり繭に含まれるフィブロイン及びセリシン、そして、桑の葉に含まれる１−デオキシノジリマイシン、Ｑ３ＭＧ、カルシウム、繊維質といった糖尿病患者やその予備軍並びにメタボリック症候群対象者に対して有用な種々の蚕由来成分を、容易に且つ同時に摂取することができ、これにより、糖尿病による食後の血糖値上昇を抑制したり、メタボリック症候群を改善したり、動脈硬化を抑制したり、或いは未病の改善など様々な有益な効果を発揮する従来に無い画期的なものとなる。 As described above, this example shows that fibroin and sericin contained in green potato, 1-deoxynojirimycin, Q3MG, calcium, and fiber contained in mulberry leaves, diabetics and their reserves, and subjects with metabolic syndrome Can be easily and simultaneously ingested with various components derived from sputum, which can prevent postprandial blood glucose level increase due to diabetes, improve metabolic syndrome, suppress arteriosclerosis, etc. Or, it will be an epoch-making thing that has never been seen before and exhibits various beneficial effects such as improvement of non-disease.
しかも、本実施例は、養蚕事業者であれば、その原材料となる繭、桑の葉のいずれもが容易に入手することが可能なので、原材料費、流通費などの製造コストを抑えることができ、製品を安価に提供することが可能となる。 Moreover, in this embodiment, if it is a sericulture business operator, it is possible to easily obtain both cocoons and mulberry leaves that are raw materials, so that manufacturing costs such as raw material costs and distribution costs can be suppressed. The product can be provided at a low cost.
尚、本実施例では、繭（フィブロインとセリシン）、桑の葉を原材料としたが、例えば、フィブロインと桑の葉、或いは、セリシンと桑の葉の組み合わせとしても良い。また、更に、ミドリムシ（ユーグレナ）を加えても良い。このミドリムシは、中性脂肪やコレステロール等の有害物質を吸着し体外へ排出するデトックス効果を得られるものとして近年注目されており、このミドリムシを更に加えることで、相乗的な効果が発揮され、より一層優れた作用効果が期待できる。 In this embodiment, cocoons (fibroin and sericin) and mulberry leaves are used as raw materials. However, for example, fibroin and mulberry leaves or a combination of sericin and mulberry leaves may be used. Further, Euglena (euglena) may be added. This Euglena has attracted attention in recent years as a detox effect that adsorbs harmful substances such as neutral fat and cholesterol and excretes it from the body, and by adding this Euglena further, a synergistic effect is exhibited, A further excellent effect can be expected.
また、本実施例における各粉末の混合割合は、本実施例に記載の割合に限定されるものではなく、適宜変更可能なものとする。 In addition, the mixing ratio of each powder in the present example is not limited to the ratio described in the present example, and can be appropriately changed.
また、本発明は、本実施例に限られるものではなく、各構成要件の具体的構成は適宜設計し得るものである。 Further, the present invention is not limited to the present embodiment, and the specific configuration of each component can be designed as appropriate.
Claims (3)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017136148A JP2019017264A (en) | 2017-07-12 | 2017-07-12 | Silkworm cocoon-derived component-containing health food |
| PCT/JP2018/025905 WO2019013172A1 (en) | 2017-07-12 | 2018-07-09 | Health food containing silkworm cocoon-derived ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017136148A JP2019017264A (en) | 2017-07-12 | 2017-07-12 | Silkworm cocoon-derived component-containing health food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2019017264A true JP2019017264A (en) | 2019-02-07 |
Family
ID=65002023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017136148A Pending JP2019017264A (en) | 2017-07-12 | 2017-07-12 | Silkworm cocoon-derived component-containing health food |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2019017264A (en) |
| WO (1) | WO2019013172A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021113168A (en) * | 2020-01-18 | 2021-08-05 | 株式会社 きものブレイン | Sheet for beauty |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252677B (en) * | 2022-05-18 | 2023-05-12 | 浙江省农业科学院 | Mulberry leaf prebiotics for regulating and controlling blood glucose homeostasis based on intestinal probiotics and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004269395A (en) * | 2003-03-07 | 2004-09-30 | Minato Pharmaceutical Co Ltd | Hypotensive action-having composition |
| JP2012125245A (en) * | 2010-12-16 | 2012-07-05 | Industry-Academic Cooperation Foundation Chonnam National Univ | Composition for manufacturing gluten-free rice noodle with hypoglycemic functionality, and production method thereof |
| CN103446503A (en) * | 2013-07-26 | 2013-12-18 | 杨德俊 | Traditional Chinese medicine composition for treating type II diabetes mellitus |
| JP2018126126A (en) * | 2017-02-09 | 2018-08-16 | 株式会社 きものブレイン | Silkworm-derived component-containing dietary supplement and method for producing the same |
-
2017
- 2017-07-12 JP JP2017136148A patent/JP2019017264A/en active Pending
-
2018
- 2018-07-09 WO PCT/JP2018/025905 patent/WO2019013172A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004269395A (en) * | 2003-03-07 | 2004-09-30 | Minato Pharmaceutical Co Ltd | Hypotensive action-having composition |
| JP2012125245A (en) * | 2010-12-16 | 2012-07-05 | Industry-Academic Cooperation Foundation Chonnam National Univ | Composition for manufacturing gluten-free rice noodle with hypoglycemic functionality, and production method thereof |
| CN103446503A (en) * | 2013-07-26 | 2013-12-18 | 杨德俊 | Traditional Chinese medicine composition for treating type II diabetes mellitus |
| JP2018126126A (en) * | 2017-02-09 | 2018-08-16 | 株式会社 きものブレイン | Silkworm-derived component-containing dietary supplement and method for producing the same |
Non-Patent Citations (5)
| Title |
|---|
| ミナトヘルスフーズ ホームページ, [ONLINE], [2018年9月3日検索],2007年,インターネット<URL:HTTP://WWW., JPN6018035871, ISSN: 0004167874 * |
| ミナトヘルスフーズ ミナト式くわ青汁, [ONLINE], [2018年9月3日検索],2007年,インターネット<URL:HTTP://, JPN6018035867, pages whole document, ISSN: 0004167872 * |
| 平成２４年度事業報告書 財団法人 大日本蚕糸会 [ONLINE], [2019年11月28日検索],平成２４年,インターネ, JPN6019047560, pages 33 - 34, ISSN: 0004167876 * |
| 蚕糸・昆虫バイオテック, 2009, VOL.78, NO.2-3, P.151-159, JPN6019047559, ISSN: 0004167875 * |
| 鈴木幸一ほか: "昆虫を資源とした生物学に基づくセラピーならびに創薬（その３）桑とシルクは天然強壮剤", PHARM TECH JAPAN, vol. Vol.30, No.3 p.87(459)-90(462), JPN6018035870, 2014, ISSN: 0004167873 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021113168A (en) * | 2020-01-18 | 2021-08-05 | 株式会社 きものブレイン | Sheet for beauty |
| JP7041899B2 (en) | 2020-01-18 | 2022-03-25 | 株式会社 きものブレイン | Beauty sheet |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019013172A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9040101B2 (en) | Method to treat diabetes utilizing a gastrointestinal microbiome modulating composition | |
| JP2008094754A (en) | Nutrient composition for diabetes or blood sugar control | |
| CN110506106A (en) | With the active novel strain and application thereof for reducing advanced glycation end products | |
| KR101695848B1 (en) | A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease | |
| JP2019017264A (en) | Silkworm cocoon-derived component-containing health food | |
| JP2018126126A (en) | Silkworm-derived component-containing dietary supplement and method for producing the same | |
| KR20110105627A (en) | Anti-obesity composition containing silkworm hemolymph | |
| KR101923603B1 (en) | A composition for anti-obesity comprising green tea complex extracts | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| JP6273440B2 (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor | |
| KR20160070912A (en) | A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract | |
| Kaddam et al. | Gum Arabic beneficial effects, clinical applications, and future prospective | |
| KR100891881B1 (en) | Composition for preventing and treating hyperlipidemia and vascular disease due to highly activated MMP comprising 3,4,5-trihydroxybenzaldehyde as an active ingredient | |
| GB2507254A (en) | Composition for reducing the consumption of food and the absorption of carbohydrate constituents thereof | |
| KR102181209B1 (en) | A composition for anti-obesity comprising edible insect protein | |
| Cantisani et al. | Unusual Food Allergy: AlioideaAllergic Reactions Overview | |
| Saeed et al. | Therapeutic properties of honey | |
| JP2016040314A (en) | Oral pharmaceutical composition and functional food | |
| WO2015190682A1 (en) | Composition for growth promotion, containing coumaric acid as active ingredient | |
| KR102609638B1 (en) | Composition comprising underia pinnatifida sporophyll hot-water extract for improving gut microbiome | |
| RU2571815C1 (en) | Therapeutic nutrient composition | |
| JP6094985B2 (en) | A novel application of hot water extract of intermediate layer with removal of rough stems in bamboo to promote bone length growth | |
| EP3235510A1 (en) | Nutritional compositions for the management of glucose metabolism | |
| JP5748492B2 (en) | Lipid excretion promoter | |
| Sanford | Reintroduction to nutrition and cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190509 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190705 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191205 |